TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11374113
Drug: Low dosage
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dosage monophasic oral contraceptives (OC) - days 19-21
Study: 11374113
Drug: Low dosage
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dosage monophasic oral contraceptives (OC) - run 5 days 5-8
Study: 11374113
Drug: Low dosage
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dosage monophasic oral contraceptives (OC) - run 5 days 19-21
Study: 9589244
Drug: high‐mixture 75/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: high‐mixture 75/25 insulin lispro/NPL insulin
Study: 9589244
Drug: mid‐mixture 50/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: mid‐mixture 50/50 insulin lispro/NPL insulin
Study: 9589244
Drug: low‐mixture 25/75
Approvals — FDA: no, EMA: no, PMDA: no
Description: low‐mixture 25/75 insulin lispro/NPL insulin
Study: 9589244
Drug: insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: insulin lispro
Study: 15278585
Drug: Atropinized group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropinized group (0.015 mg.kg(‐1) i.m.)
Study: 3924984
Drug: Cromolyn Sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn Sodium (CS) 20 mg inhaled four times daily
Study: 3924984
Drug: Long-acting Theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting Theophylline (LAT) administered twice daily to achieve mean blood levels of 14.0 +/- 1.6 SEM micrograms per milliliters
Study: 30272170
Drug: Dulaglutide (Trulicity®)
Normalized name: Dulaglutide
DrugBank: Dulaglutide (DB09045)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dulaglutide (Trulicity®) 1.5 mg
Study: 29160002
Drug: Topical anesthetic
Normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical anesthetic (TA) cream
Study: 26775671
Drug: 5‐aminolevulinic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐aminolevulinic acid photodynamic therapy (ALA‐PDT), 4 sessions at 2‐week intervals
Study: 26775671
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate (0.05%), daily for 8 weeks
Study: 26775671
Drug: 5‐aminolevulinic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐aminolevulinic acid photodynamic therapy (ALA‐PDT)
Study: 15048062
Drug: Rescue therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue therapy combining amsacrine 120 mg/m(2)/day (days 1-3), cytarabine 1 g/m(2)/12 h (days 1-5), and etoposide 100 mg/m(2)/day (days 1-5)
Study: 15048062
Drug: Rescue therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue therapy combining amsacrine, cytarabine, and etoposide
Study: 8556567
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (FPANS) containing BKC
Study: 2169077
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (subcutaneous injection once daily)
Study: 40584
Drug: Oral cimetidine
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cimetidine (1 g daily for 1 week)
Study: 40584
Drug: H1 receptor
Normalized name: Histamine H1 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1 receptor antagonist chlorpheniramine
Study: 31587493
Drug: PDT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDT with active formulation cream (licochalcone A, L-carnitine, and decanediol)
Study: 31587493
Drug: PDT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDT with active formulation cream
Study: 31587493
Drug: PDT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDT with vehicle cream
Study: 21696114
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene indices (VPI and GBI)
Study: 19432036
Drug: Intermittent balneotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent balneotherapy in a sulfur pool heated to 35-36 degrees C, twice weekly for 6 weeks
Study: 11401935
Drug: Deferoxamine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferoxamine (500 mg intra-arterially over 1 hour)
Study: 8010314
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dexamethasone and metoclopramide
Study: 27836586
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for presumed adverse events (administration of antibiotics, misoprostol or surgical evacuation).
Study: 27836586
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for presumed adverse events in the control group.
Study: 11403977
Drug: Buserelin (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buserelin (low dose gonadotropin releasing hormone agonist)
Study: 8214647
Drug: Amrinone (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amrinone (1.5 mg/kg)
Study: 8214647
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of amrinone and epinephrine
Study: 28669606
Drug: 150 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 minutes per week of aerobic exercise (low-dose)
Study: 28669606
Drug: 300 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 minutes per week of aerobic exercise (high-dose)
Study: 27391774
Drug: Intradialytic exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradialytic exercise programme (30 min continuous cycling thrice weekly during dialysis)
Study: 24215215
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of cefazolin (CEZ)
Study: 22334806
Drug: Unattended polysomnography
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unattended polysomnography at baseline and auto-titrating CPAP therapy for up to one year
Study: 18357500
Drug: Stanger bath
Normalized name: Stangard
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stanger bath therapy and exercise program (n = 30)
Study: 16522454
Drug: FSC 100/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSC 100/50 microg twice daily
Study: 16522454
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 250 microg twice daily
Study: 11075843
Drug: Rizatriptan wafer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rizatriptan wafer 10 mg
Study: 8792758
Drug: Electroconvulsive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive therapy (ECT) with high dosage and bilateral electrode placement
Study: 8792758
Drug: Electroconvulsive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive therapy (ECT) with low dosage and right unilateral electrode placement
Study: 31590426
Drug: Cyano-B12 (CN-B12)
Normalized name: Coenzyme B12
DrugBank: Cobamamide (DB11191)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyano-B12 (CN-B12) capsules (2 × 2.8 µg/day)
Study: 31590426
Drug: Cyano-B12 (CN-B12)
Normalized name: Coenzyme B12
DrugBank: Cobamamide (DB11191)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyano-B12 (CN-B12) capsules
Study: 29911775
Drug: Silver nanoparticle
Normalized name: Silver nanoparticle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver nanoparticle gel with 2.5% benzoyl peroxide
Study: 29911775
Drug: Clindamycin gel
Normalized name: clindamycin Topical Gel
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin gel with 2.5% benzoyl peroxide
Study: 17580443
Drug: Medication (Amitriptyline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (Amitriptyline 50 mg/d initially, increased to 200 mg/d)
Study: 9934405
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (40 mcg) inhaled before the methacholine test
Study: 31965573
Drug: Hypovolaemic phlebotomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypovolaemic phlebotomy (7-10 ml per kg whole blood removed, without intravenous fluid replacement)
Study: 28060581
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (n = 20)
Study: 17216727
Drug: Saccharine (22.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharine (22.5 mg)
Study: 17216727
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of saccharine (22.5 mg) and cyclamate (150 mg)
Study: 14584388
Drug: Pranlukast therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranlukast therapy for 4 weeks, continued for Group I for an additional two years.
Study: 14584388
Drug: Pranlukast therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranlukast therapy continued for Group II for one more year after showing a 5% or greater increase in PEFR after one year.
Study: 14584388
Drug: Medication was
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication was suspended for Group III after failing to show improvement in PEFR after one year.
Study: 8879928
Drug: Patch testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch testing with serial dilutions of isoeugenol
Study: 8879928
Drug: Patch testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch testing with isoeugenol
Study: 11073141
Drug: Cefminox 2
Normalized name: cefminox
DrugBank: Cefminox (DB09062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefminox 2 g/12 h
Study: 11073141
Drug: Metronidazole 500
Normalized name: metronidazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 500 mg/8 h and Gentamicin 80 mg/8 h (M+G)
Study: 1529929
Drug: Intravenous nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nitroglycerin (short-term) with or without long-acting nitrates (chronic)
Study: 15762903
Drug: Guideline-based care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-based care suggestions delivered to physicians and pharmacists when writing orders or filling prescriptions using computer workstations.
Study: 12090977
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of anastrozole plus tamoxifen
Study: 2011161
Drug: Mifepristone (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (12.5 or 25 mg per kilogram of body weight)
Study: 6119183
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of metipranolol and isosorbide‐5‐mononitrate
Study: 23789885
Drug: High-MW β-glucan
Normalized name: marine non-gelling gelatin, high MW
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-MW β-glucan (4 g)
Study: 23789885
Drug: Low-MW β-glucan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-MW β-glucan (4 g)
Study: 23789885
Drug: 250 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 ml β-glucan beverage
Study: 23789885
Drug: 600 ml
Normalized name: urinary bag 600 mL-10" MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 ml β-glucan beverage
Study: 22022222
Drug: Learning style-tailored
Approvals — FDA: no, EMA: no, PMDA: no
Description: Learning style-tailored education materials (information prescriptions)
Study: 19226535
Drug: Rapid tryptophan
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rapid tryptophan depletion (RTD) administered within an amino acid drink lacking tryptophan
Study: 16445305
Drug: Bemiparin plus
Normalized name: bemiparin
DrugBank: Bemiparin (DB09258)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bemiparin plus oral anticoagulants (OAC) for 3 months
Study: 16445305
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) plus OAC
Study: 14727208
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B deoxycholate (1 mg/kg on alternate days for 30 days)
Study: 14727208
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (2 mg/kg per day for 5 days)
Study: 14727208
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B lipid complex (2 mg/kg per day for 5 days)
Study: 22776409
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D deficiency (defined as serum 25(OH)vitamin D <20 ng/mL)
Study: 20356486
Drug: 7-day levofloxacin-based
Normalized name: Levofloxacine
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7-day levofloxacin-based triple therapy (amoxicillin, levofloxacin, lansoprazole)
Study: 20356486
Drug: 7-day standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day standard triple therapy (clarithromycin, amoxicillin, lansoprazole)
Study: 12107601
Drug: Suplatast tosilate
Normalized name: Edoxaban Tosylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suplatast tosilate (100 mg three times daily)
Study: 10095821
Drug: 800 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 micrograms day‐1 of inhaled budesonide
Study: 10095821
Drug: 1600 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600 micrograms day‐1 of inhaled budesonide
Study: 10095821
Drug: 800 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 micrograms day‐1 of inhaled budesonide plus placebo
Study: 10095821
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg day‐1 of prednisone
Study: 7477193
Drug: High-dose nadroparin
Normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose nadroparin (4100 anti-factor Xa IU twice daily)
Study: 7477193
Drug: Low-dose nadroparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose nadroparin (4100 IU once daily)
Study: 24484373
Drug: Online cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online cognitive-behavioral therapy (CBT) for pain management + standard care (n = 17)
Study: 24484373
Drug: Online cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online cognitive-behavioral therapy (CBT) for pain management
Study: 22100010
Drug: Managing Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Managing Oral Hygiene Using Threat Reduction
Study: 19018805
Drug: Fluoxetine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine plus tri‐iodothyronine (T(3))
Study: 15565603
Drug: 180 mug
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mug pegylated interferon alpha‐2a once weekly plus daily ribavirin
Study: 11686357
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (100 IU/kg bolus followed by infusion for 3 days, titrated to maintain aPTT between 70 and 90 s)
Study: 7874374
Drug: Pancuronium (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium (0.1 mg/kg i.v.)
Study: 7874374
Drug: Pipecuronium (0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pipecuronium (0.07 mg/kg i.v.)
Study: 2896868
Drug: Branched-chain amino
Normalized name: Branched-chain amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branched-chain amino acids (12 g L-leucine, 8 g L-isoleucine, 6.4 g L-valine)
Study: 24391768
Drug: Quadrivalent HPV
Normalized name: HPV, quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent HPV vaccine (Gardasil™)
Study: 18436090
Drug: Standard dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dialysis regimen (4 hours 3 times weekly)
Study: 10930964
Drug: Elixir (30-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elixir (30-40 mg kg-1)
Study: 10930964
Drug: Glycogelatin capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycogelatin capsule suppository (30-40 mg kg-1)
Study: 10930964
Drug: Triglyceride base
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triglyceride base suppository (30-40 mg kg-1)
Study: 10930964
Drug: Elixir
Normalized name: Elixir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elixir
Study: 31648910
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of quadrivalent HPV vaccine at 6 months interval
Study: 24522201
Drug: Quinine MR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine MR with 10 mg rifampicin
Study: 24522201
Drug: Quinine MR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine MR with 20 mg rifampicin
Study: 24522201
Drug: Quinine MR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine MR with 100 mg rifampicin
Study: 15139942
Drug: Intravenous patient-controlled-analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled-analgesia
Study: 11813383
Drug: Rinsing with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rinsing with a higher volume of water (10 x 3 mL)
Study: 11813383
Drug: Rinsing with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rinsing with a lower volume of water (5 mL)
Study: 7995001
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ketoconazole
Study: 2691002
Drug: 2.5% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% glucose + glucose polymer (group G + GP)
Study: 2691002
Drug: 2.5% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% glucose (group G)
Study: 812895
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium powder, 20 mg three times daily
Study: 28954261
Drug: Atraumatic Restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic Restorative Treatment (ART) with High-Viscosity Glass-Ionomer Cement (HVGIC) sealants
Study: 22615291
Drug: Tablet A
Normalized name: tablet administration aid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet A (100 mg)
Study: 22615291
Drug: Tablet B
Normalized name: Biaxin 4 Tablet Blister Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet B (100 mg)
Study: 6683539
Drug: Capsule (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule (100 mg)
Study: 22615291
Drug: Oral suspension
Normalized name: Oral Suspension
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral suspension (control)
Study: 22615291
Drug: All formulations
Normalized name: Novel Influenza-H1N1-09, all formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: All formulations of posaconazole (100 mg)
Study: 17433383
Drug: Vision Restoration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vision Restoration Therapy (VRT)
Study: 12555626
Drug: Transdermal 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 10 mg nitroglycerine patch (12 hours)
Study: 12555626
Drug: Long-acting oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting oral 40 mg isosorbide-5-mononitrate (once a day)
Study: 2195921
Drug: Combination methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination methylprednisolone and placebo troleandomycin
Study: 2195921
Drug: Troleandomycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troleandomycin (250 mg once daily or every other day)
Study: 2195921
Drug: Low-dose TAO
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose TAO combined with MPn
Study: 391624
Drug: Cinnarizine treatment
Normalized name: cinnarizine
DrugBank: Cinnarizine (DB00568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnarizine treatment
Study: 29951850
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy (n = 20)
Study: 19458319
Drug: Dose-matched CIMT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-matched CIMT
Study: 19458319
Drug: Traditional UE
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional UE therapy (Control)
Study: 17877827
Drug: Room temperature
Normalized name: ROOM DEODORIZER POWDER MENTOR #3202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room temperature irrigation and intravenous fluids
Study: 17877827
Drug: Warmed irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warmed irrigation fluid at 38 degrees C and room temperature intravenous fluid
Study: 17877827
Drug: Warmed irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warmed irrigation fluid and warmed intravenous fluids at 38 degrees C
Study: 14687858
Drug: sertraline (50‐200
Approvals — FDA: no, EMA: no, PMDA: no
Description: sertraline (50‐200 mg/day)
Study: 14687858
Drug: imipramine (75‐225
Approvals — FDA: no, EMA: no, PMDA: no
Description: imipramine (75‐225 mg/day)
Study: 12109659
Drug: Very-high-flow injection-rate
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very-high-flow injection-rate method (group A)
Study: 12109659
Drug: Conventional injection-rate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional injection-rate method (group B)
Study: 8948688
Drug: Nifedipine (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (average daily dose, 21.5 mg/day) for 4 weeks
Study: 1632260
Drug: Intranasal budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal budesonide 200 micrograms b.i.d.